Nanostics Raises Funding for ClarityDX® Test Expansion in North America

Nanostics Receives Funding from University of Alberta Innovation Fund

Key Highlights:

• Funding: Nanostics, a precision health company, secured funding from the University of Alberta Innovation Fund.
• Test Adoption: The funds will be used to drive the adoption of Nanostics' ClarityDX® platform technology test in North America.

Nanostics' Target Market

• Target Market: Healthcare providers, clinics, and hospitals specializing in cancer diagnosis and treatment.
• Prostate Cancer Screening: Men suspected of prostate cancer, especially those with high prostate-specific antigen (PSA) test results.
• Precision Health: Organizations and individuals interested in advanced diagnostic tests and personalized medicine.

What Nanostics Needs to Buy

• Marketing and Sales Support: Services to promote and market the ClarityDX Prostate test to healthcare providers and potential customers.
• Research and Development Collaboration: Partnerships with research institutions and organizations to further develop and enhance their diagnostic tests.
• Regulatory Compliance Services: Assistance in navigating regulatory requirements and obtaining necessary approvals for their diagnostic tests.